Nanotechnology Now - Press Release: Cerulean Pharma Inc. to Convene Nanomedicine Pioneers at 2010 American Chemical Society (ACS) National Meeting & Exposition in Boston

Home > Press > Cerulean Pharma Inc. to Convene Nanomedicine Pioneers at 2010 American Chemical Society (ACS) National Meeting & Exposition in Boston

Abstract:
ACS Symposium Will Examine Nanotechnology's Potential Impact on Developing Improved Therapies and Diagnostics to Address a Broad Range of Diseases

Cerulean Pharma Inc. to Convene Nanomedicine Pioneers at 2010 American Chemical Society (ACS) National Meeting & Exposition in Boston

Cambridge, MA | Posted on August 19th, 2010

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced it will assemble a group of leading scientific experts at the American Chemical Society's ("ACS") 240th National Meeting & Exposition for a three-day thought leadership summit on the advancement of nanotechnology in the pharmaceutical and diagnostic industries. ACS, which bills itself as the world's largest scientific society, will host its national meeting from August 22 through August 26 at the Boston Convention and Exhibition Center in Boston, Massachusetts.

The inaugural symposium, titled "Multifunctional Nanoparticles for Drug Delivery and Imaging," will feature close to 60 oral and poster presentations from renowned U.S. and international researchers. Key themes will include diagnostic imaging, experimental therapy, and drug delivery technologies for therapeutic agents ranging from small molecules and peptides, to new classes of therapies such as siRNA.

"Nanotechnology has the potential to revolutionize medicine by improving the safety, efficacy, and bioavailability of therapies," said Robert S. Langer, Ph.D., David H. Koch Institute Professor at the Massachusetts Institute of Technology and a keynote speaker at the nanotechnology summit. "An ACS National Meeting symposium, focused on the key role nanotechnology will play in the future of medicine, represents significant validation for this exciting research area."

Dr. Langer will deliver his keynote address on Sunday, August 22, highlighting the most promising potential applications of nanotechnology in medicine. A second keynote address will be delivered on Monday, August 23, by Piotr Grodzinski, Ph.D., Director of the National Cancer Institute (NCI) Alliance for Nanotechnology in Cancer, which will focus on the latest development in nanotechnology-based cancer therapy.

"ACS is a premier global scientific organization whose decision to highlight nanotechnology in medicine lends significant credibility to this emerging field," said Oliver Fetzer, Ph.D., President and Chief Executive Officer of Cerulean.

"We are excited to convene leading scientific experts who are shaping the future of this promising research area," added John Ryan, Ph.D., M.D., Cerulean's Chief Medical Officer. "Cerulean is committed to continuing its leadership position in nanopharmaceuticals by advancing its clinical and pre-clinical programs, and by creating opportunities for thought leaders to gather and discuss new discoveries and advances in the technology."

At the symposium, Dr. Ryan will be presenting data on CRLX101 (formerly IT-101), Cerulean's clinical nanopharmaceutical drug candidate in Phase 2a development. Company scientists will also be presenting data on CRLX288, one of Cerulean's pre-clinical development candidates, details of which will be revealed for the first time at this symposium.

Copies of Cerulean's oral and poster presentation abstracts are available at abstracts.acs.org/chem/240nm/program/divisionindex.php by searching the term "Cerulean"

####

About Cerulean Pharma
Cerulean Pharma Inc. is a clinical-stage company specializing in the design and development of nanopharmaceuticals optimized to make drugs more effective and with fewer side effects. Cerulean is applying its proprietary nanopharmaceutical platform technologies and specialized capabilities to advance a new class of therapeutic agents for diseases with unmet medical needs. With an initial focus in oncology, the Company's technology platform can be readily applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs. Cerulean is privately financed and funded by experienced healthcare investors, including Polaris Venture Partners, Venrock, Lux Capital, Bessemer Venture Partners, and William H. Rastetter. Cerulean is located in Cambridge, Massachusetts.

For more information, please click here

Contacts:
Schwartz Communications
Andrew Law/Benjamin Navon
+1 781-684-0770
cerulean@schwartzcomm.com

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: